

03-14-05

B/1647\$
JRWDocket No: G15358-CIP
PatentIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: Kenneth JACOBS, et al
Application No.: 10/084,298 Group Art No.: 1647
Filed: February 25, 2002 Examiner: Rachel K. Hunnicut
For: COMPOSITION AND METHOD FOR TREATING INFLAMMATORY
DISORDERS
Confirmation No.: 7985
Customer Number: 25291

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information which were cited in a Search Report for an international application related to the above-identified application.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV238505128US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

3/11/05
Date

Kerry A. Ovidio

03/15/2005 EABUBAK1 00000106 071060 10084298
01 FC:1806 180.00 DA

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
- b. ☐ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☒ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☒ Certification under 37 CFR 1.97(e) and 1.704(d)
The undersigned attorney certifies

- a. ☒ that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application (PCT/US2004/020833) not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☒ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed. Except that no copy of patents or publications previously made of record is included.

☐ Previously Cited Information
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.

Prior application is Application Number _____, filed on _____ of _____ for _____.

- ☐ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☒ Fees
- ☒ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:
Charge Deposit Account No. 07-1060 in the amount of \$180.00
A duplicate of this statement is enclosed.


Instructions as to Overpayment/Underpayment:
Credit any overpayment and charge any underpayment to Deposit Account No. 07-1060.



Diana M. Collazo
Attorney for Applicants
Reg. No. 46,635

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (617) 665-6073

S:\LACOMMON\PATENTS\AMEND\5358\CIP\Supp IDS 03.10.05.doc

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
		Application Number	10/084,298		
		Filing Date	February 25, 2002		
		First Named Inventor	Kenneth JACOBS		
		Group Art Unit	1647		
		Examiner Name	Rachel K. Hunnicut		
Sheet	1	of	1	Attorney Docket Number	GI5358-CIP

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	1.		WO2002/16611		Genentech Inc.	02-28-2002		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	2.	R&D Systems, Catalog NR, AF582, XP002307633, "Anti-Mouse IL-22 Antibody", August 22, 2002	<input type="checkbox"/>
	3.	Kotenko, Sergei, "The Family of IL-10-Related Cytokines and Receptors: Related, But to What Extent?", Cytokine and Growth Factor Reviews, vol. 13, no. 3, June 2002, pages 223-240	<input type="checkbox"/>
	4.	Resmini, Christine, et al, "An Anti-Murine IL-22 Monoclonal Antibody Decreases Disease Severity in a Murine Model of Collagen Induced Arthritis", European Cytokine Network, vol. 14, no. Supplement 3, September, 2003, page 129 and Annual Meeting of the International Cytokine Society; Dublin, Ireland, September 20-24, 2003, ISSN: 1148-5493	<input type="checkbox"/>
	5.	Li, J., et al, "Temporal Associations Between Interleukin 22 and the Extracellular Domains of IL-22R and IL-10R2", International Immunopharmacology, Elsevier, Amsterdam, NL, vol. 4, no. 5, May 2004, pages 693-708	
	6.	International Search Report for International Application No. PCT/US2004/020833	

S:\LACOMMON\PATENTS\AMEND\5358\CIP\PTO 1449 03.10.05.doc

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.